tran may be a novel management option for this distressing and difficult-to-treat condition. Further investigations to elucidate the mechanism of action and use of dabigatran in patients with GET are merited.

Anna Ascott, MBBS
Elian Karim, BS
Ruth Lawless, MBChB, BSc
Arjida Woollons, MD

Author Affiliations: Department of Dermatology, University Hospitals Sussex NHS Foundation Trust, Worthing Hospital, Worthing, West Sussex, England (Ascott, Lawless, Woollons); Brighton and Sussex Medical School, BSMS Teaching Building, University of Sussex, Brighton, East Sussex, England (Karim).

Corresponding Author: Ruth Lawless, MBChB, BSc, Dermatology Department, University Hospitals Sussex National Health Service Foundation Trust, Worthing Hospital, Lyndhurst Road, Worthing, West Sussex BN11 2DH, England (ruth.lawless@nhs.net).

Published Online: April 19, 2023. doi:10.1001/jamadermatol.2023.0757

Conflict of Interest Disclosures: None reported.

Additional Contributions: We thank the patient for granting permission to publish this information. We also thank Jerry Grant, MD, Western Sussex Hospitals, for interpreting the histopathology for this case. He was not compensated for his contributions.


CORRECTION

Errors in Abstract, Results, Table 1, and Supplement 1: In the Original Investigation titled “Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial,” published online April 19, 2023, percentages were mistakenly reported with mean changes in SCORing Atopic Dermatitis in the Abstract, several values were misstated in Table 1 and Supplement 1, and minor errors in percentages not affecting the results of the study were present and text regarding Children’s Dermatology Life Quality Index reductions at week 16 missing in Results. This article has been corrected.


Updates to Article Text, Figure, and Figure Caption: The Editorial titled “Legislative Efforts Restricting Care for Transgender People: Implications for Dermatologists and Patients,” published online April 26, 2023, has been updated to reflect additional legislation introduced in Louisiana and Minnesota and signed into law in Florida, Idaho, Indiana, Montana, North Dakota, and Oklahoma. This article has been corrected.